Literature DB >> 33425786

Sugar-Coated Killer: Serotype 3 Pneumococcal Disease.

Jennifer N Luck1, Hervé Tettelin2, Carlos J Orihuela1.   

Abstract

Capsular polysaccharide (CPS), which surrounds the bacteria, is one of the most significant and multifaceted contributors to Streptococcus pneumoniae virulence. Capsule prevents entrapment in mucus during colonization, traps water to protect against desiccation, can serve as an energy reserve, and protects the bacterium against complement-mediated opsonization and immune cell phagocytosis. To date, 100 biochemically and serologically distinct capsule types have been identified for S. pneumoniae; 20 to 30 of which have well-defined propensity to cause opportunistic human infection. Among these, serotype 3 is perhaps the most problematic as serotype 3 infections are characterized as having severe clinical manifestations including empyema, bacteremia, cardiotoxicity, and meningitis; consequently, with a fatality rate of 30%-47%. Moreover, serotype 3 resists antibody-mediated clearance despite its inclusion in the current 13-valent conjugate vaccine formulation. This review covers the role of capsule in pneumococcal pathogenesis and the importance of serotype 3 on human disease. We discuss how serotype 3 capsule synthesis and presentation on the bacterial surface is distinct from other serotypes, the biochemical and physiological properties of this capsule type that facilitate its ability to cause disease, and why existing vaccines are unable to confer protection. We conclude with discussion of the clonal properties of serotype 3 and how these have changed since introduction of the 13-valent vaccine in 2000.
Copyright © 2020 Luck, Tettelin and Orihuela.

Entities:  

Keywords:  Streptococcus pneumoniae; capsule production; invasive pneumococcal disease; serotype 3; synthase-dependent pathway; vaccine escape; wzy-dependent pathway

Year:  2020        PMID: 33425786      PMCID: PMC7786310          DOI: 10.3389/fcimb.2020.613287

Source DB:  PubMed          Journal:  Front Cell Infect Microbiol        ISSN: 2235-2988            Impact factor:   5.293


  102 in total

Review 1.  Status of methods for assessing bacterial cell surface charge properties based on zeta potential measurements.

Authors:  W W Wilson; M M Wade; S C Holman; F R Champlin
Journal:  J Microbiol Methods       Date:  2001-01       Impact factor: 2.363

Review 2.  Pneumococcal vaccines: history, current status, and future directions.

Authors:  J C Butler; E D Shapiro; G M Carlone
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

3.  Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae.

Authors:  J O Kim; J N Weiser
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

Review 4.  Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults.

Authors:  John D Grabenstein; Luwy K Musey
Journal:  Vaccine       Date:  2014-03-14       Impact factor: 3.641

5.  Assignment of Opsonic Values to Pneumococcal Reference Serum 007sp for Use in Opsonophagocytic Assays for 13 Serotypes.

Authors:  R L Burton; J Antonello; D Cooper; D Goldblatt; K H Kim; B D Plikaytis; L Roalfe; D Wauters; F Williams; G L Xie; M H Nahm; M Akkoyunlu
Journal:  Clin Vaccine Immunol       Date:  2017-02-06

Review 6.  Serotype Replacement in Adult Pneumococcal Pneumonia after the Introduction of Seven-Valent Pneumococcal Conjugate Vaccines for Children in Japan: a Systematic Literature Review and Pooled Data Analysis.

Authors:  Shungo Katoh; Motoi Suzuki; Koya Ariyoshi; Konosuke Morimoto
Journal:  Jpn J Infect Dis       Date:  2017-03-28       Impact factor: 1.362

7.  TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness.

Authors:  Richard Graveline; Mariela Segura; Danuta Radzioch; Marcelo Gottschalk
Journal:  Int Immunol       Date:  2007-02-16       Impact factor: 4.823

8.  Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates.

Authors:  Luanne Hall-Stoodley; Laura Nistico; Karthik Sambanthamoorthy; Bethany Dice; Duc Nguyen; William J Mershon; Candice Johnson; Fen Ze Hu; Paul Stoodley; Garth D Ehrlich; J Christopher Post
Journal:  BMC Microbiol       Date:  2008-10-08       Impact factor: 3.605

9.  THE PROTECTIVE ACTION OF A SPECIFIC ENZYME AGAINST TYPE III PNEUMOCOCCUS INFECTION IN MICE.

Authors:  O T Avery; R Dubos
Journal:  J Exp Med       Date:  1931-06-30       Impact factor: 14.307

10.  The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination.

Authors:  Hans-Christian Slotved; Tine Dalby; Zitta Barrella Harboe; Palle Valentiner-Branth; Victoria Fernandez de Casadevante; Laura Espenhain; Kurt Fuursted; Helle Bossen Konradsen
Journal:  Heliyon       Date:  2016-11-29
View more
  12 in total

1.  The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.

Authors:  Eiman Mokaddas; Shabeera Syed; M John Albert
Journal:  Hum Vaccin Immunother       Date:  2021-08-26       Impact factor: 4.526

2.  Influence of the Polysaccharide Capsule on the Bactericidal Activity of Indolicidin on Streptococcus pneumoniae.

Authors:  Natalha T Waz; Sheila Oliveira; Raquel Girardello; Nilton Lincopan; Giovana Barazzone; Thais Parisotto; Anders P Hakansson; Thiago Rojas Converso; Michelle Darrieux
Journal:  Front Microbiol       Date:  2022-05-13       Impact factor: 6.064

Review 3.  Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease.

Authors:  William Walkowski; Justin Bassett; Manmeet Bhalla; Blaine A Pfeifer; Elsa N Bou Ghanem
Journal:  Vaccines (Basel)       Date:  2021-06-02

4.  Antimicrobial Susceptibility Pattern and Serotype Distribution of Streptococcus pneumoniae Isolates From a Hospital-Based Study in Chandigarh, North India.

Authors:  Swati Sharma; Monica Sharma; Pallab Ray; Anuradha Chakraborti
Journal:  Cureus       Date:  2022-01-19

Review 5.  Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies.

Authors:  Aaron D Gingerich; Jarrod J Mousa
Journal:  Front Cell Infect Microbiol       Date:  2022-01-28       Impact factor: 5.293

6.  Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2).

Authors:  Konstantinos Liatsikos; Angela Hyder-Wright; Sherin Pojar; Tao Chen; Duolao Wang; Kelly Davies; Christopher Myerscough; Jesus Reine; Ryan E Robinson; Britta Urban; Elena Mitsi; Carla Solorzano; Stephen B Gordon; Angela Quinn; Kaijie Pan; Annaliesa S Anderson; Christian Theilacker; Elizabeth Begier; Bradford D Gessner; Andrea Collins; Daniela M Ferreira
Journal:  BMJ Open       Date:  2022-07-07       Impact factor: 3.006

7.  A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.

Authors:  Ahmet Ozdilek; Jiachen Huang; Rachelle Babb; Amy V Paschall; Dustin R Middleton; Jeremy A Duke; Liise-Anne Pirofski; Jarrod J Mousa; Fikri Y Avci
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

8.  Pneumococcal Disease Prevention: Are We on the Right Track?

Authors:  Nicola Principi; Susanna Esposito
Journal:  Vaccines (Basel)       Date:  2021-03-24

Review 9.  Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines.

Authors:  Ninecia R Scott; Beth Mann; Elaine I Tuomanen; Carlos J Orihuela
Journal:  Vaccines (Basel)       Date:  2021-03-02

Review 10.  [Pneumococcal vaccination].

Authors:  Mathias W Pletz; Christina Bahrs
Journal:  Internist (Berl)       Date:  2021-07-12       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.